Moderna, Inc.
MRNAModerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +29.2%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +13,550.0%
Quarter to September 2026, against a year earlier
After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.
Follow MRNA
Alert me
Moderna, Inc. (MRNA) P/S ratio
As of Nov 20, 2026, Moderna, Inc. (MRNA) trades at a P/S ratio of 31.0×. Over the past ten years it has ranged from 2.0× (September 2022) to 543× (May 2020); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 8.6× and above the Healthcare sector median of 3.2×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 5.9× | 19.60% |
| FY2024 | 4.9× | (21.38%) |
| FY2023 | 6.3× | 71.42% |
| FY2022 | 3.7× | (33.93%) |
| FY2021 | 5.5× | (88.82%) |
| FY2020 | 49.6× | (54.06%) |
| FY2019 | 108× | 1,076.69% |
| FY2018 | 9.2× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 30.6× | 144.47% |
| Jun 2026 | 12.5× | 38.71% |
| Mar 2026 | 9.0× | 52.83% |
| Dec 2025 | 5.9× | 30.75% |
| 31 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | 5.5× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.7× |
| GMAB Genmab A/S Sponsored ADR compare | 7.2× |
| ARGX argenex SE compare | 9.8× |
| VRTX Vertex Pharmaceuticals Incorporated compare | 10.1× |
| RPRX Royalty Pharma PLC compare | 11.7× |
| INSM Insmed, Inc. compare | 20.3× |
| MRNA Moderna, Inc. | 31.0× |
| RVMD Revolution Medicines, Inc. compare | 166× |
| Biotechnology industry median | 8.6× |
| Healthcare sector median | 3.2× |
| Market median | 1.7× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement